Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

@article{Green2006InhibitionOD,
  title={Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.},
  author={Brian Desmond Green and Nigel Irwin and Nicola A Duffy and Victor A Gault and Finbarr P M O'harte and Peter Raymond Flatt},
  journal={European journal of pharmacology},
  year={2006},
  volume={547 1-3},
  pages={192-9}
}
GLP-1 and GIP are insulin-releasing 'incretin' hormones inactivated following degradation by dipeptidyl peptidase IV. Incretin hormone analogues resistant to degradation by DPP IV, as well as, inhibitors of DPP IV are in development as novel treatments for type 2 diabetes. The biguanide metformin is an oral agent commonly prescribed to treat type 2 diabetes. Antidiabetic actions of metformin involve the reduction of hepatic glucose production and/or insulin resistance. Recent reports indicate… CONTINUE READING